Hutchison China MediTech Limited logo
Hutchison China MediTech Limited HCM
$ 14.31 0.77%
report update icon

Quarterly report 2025-Q4
added 05-12-2026

Hutchison China MediTech Limited Financial Statements 2025-2011 | HCM

Annual Financial Statements Hutchison China MediTech Limited

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

12 B 12.8 B 12.8 B 11.3 B 21.6 B 20.1 B 15.5 B 17.3 B 20.8 B 843 M - - - - -

Shares

858 M 855 M 850 M 847 M 793 M 698 M 666 M 664 M 617 M 59.7 M - - - - -

Historical Prices

14 15 15.1 13.3 27.2 28.7 23.3 26.1 33.7 12.7 - - - - -

Net Income

457 M 37.7 M 101 M -361 M -195 M -126 M -106 M -74.8 M -26.7 M -43 M 7.99 M 5.37 M 5.92 M 3.64 M 710 K

Revenue

549 M 630 M 838 M 426 M 356 M 228 M 205 M 214 M 241 M 216 M 178 M 91.8 M 46 M 195 M 167 M

Cost of Revenue

336 M 349 M 384 M 311 M 91.6 M 63.5 M 46.2 M 35.3 M 24.8 M 21.7 M 17.3 M - - - -

Gross Profit

- - - - - 39.5 M 205 M 214 M 241 M 216 M 67.4 M 19.8 M 23.8 M 96 M 92.8 M

Operating Income

-39.2 M -43.7 M 18.4 M -408 M -328 M -197 M -146 M -92.6 M -53.4 M -46.7 M -9.77 M -18.3 M - - -

Interest Expense

- - 759 K 652 K 592 K 787 K 1.03 M 1.01 M 1.46 M 1.63 M 1.4 M 1.52 M - - -

EBITDA

-25.9 M -31.4 M 26.6 M -399 M -321 M -191 M -141 M -89.1 M -50.8 M -46.7 M -7.76 M -5.92 M -87 K 2.64 M 9.91 M

Operating Expenses

- - - - - 236 M 190 M 163 M 119 M 106 M 77.2 M 26.9 M 24.8 M 97.4 M 87.2 M

General and Administrative Expenses

66.7 M 64.3 M 79.8 M 92.2 M 89.3 M 50 M 39.2 M 30.9 M 24 M - 19.6 M 22.6 M 21.3 M 35.7 M -

All numbers in USD currency

Quarterly Income Statement Hutchison China MediTech Limited

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

858 M 857 M 855 M 856 M 850 M 847 M - - - - - - - - - - - - - - - 665 M - - - 664 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

457 M 455 M 37.7 M 25.8 M 101 M 169 M - - - - - - - - - - - - - - - -19.9 M - - - -11.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

549 M 278 M 630 M 306 M 838 M 533 M - - - - - - - - - - - - - - - 52.2 M - - - 52.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

336 M 168 M 349 M 36.9 M 384 M 45.4 M - - - - - - - - - - - - - - - 11.3 M - - - 7.85 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-39.2 M -3.51 M -43.7 M -27.5 M 18.4 M 112 M - - - - - - - - - - - - - - - -36 M - - - -25 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- 21.6 M - 1.48 M 759 K 224 K - - - - - - - - - - - - - - - 260 K - - - 206 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-25.9 M 2.6 M -31.4 M -21.3 M 26.6 M 115 M - - - - - - - - - - - - - - - -34.8 M - - - -24.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

66.7 M 27.8 M 64.3 M 30.5 M 79.8 M 41.8 M - - - - - - - - - - - - - - - 10.2 M - - - 7.02 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Hutchison China MediTech Limited HCM
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Hutchison China MediTech Limited plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 66.14 0.51 % $ 12.7 B usaUSA
BioCardia BioCardia
BCDA
$ 1.09 4.81 % $ 7.27 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 8.1 0.31 % $ 1.7 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 4.01 18.64 % $ 278 M britainBritain
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.94 2.65 % $ 110 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 25.67 4.78 % $ 2.54 B usaUSA
Biogen Biogen
BIIB
$ 223.59 1.69 % $ 32.8 B usaUSA
BioVie BioVie
BIVI
$ 1.44 0.68 % $ 2.13 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.32 0.43 % $ 5.72 B israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 57.54 0.63 % $ 11 B usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 58.81 0.53 % $ 120 B usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 9.23 2.78 % $ 430 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 97.64 0.76 % $ 23.6 B germanyGermany
Burford Capital Limited Burford Capital Limited
BUR
$ 3.55 0.51 % $ 778 M britainBritain
BeyondSpring BeyondSpring
BYSI
$ 0.79 2.12 % $ 32.5 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 2.08 4.0 % $ 209 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.14 0.45 % $ 3.52 M israelIsrael
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 7.78 0.11 % $ 362 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 13.94 0.42 % $ 1.25 B usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 2.99 1.36 % $ 248 M usaUSA
Codexis Codexis
CDXS
$ 1.39 2.21 % $ 121 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.34 2.63 % $ 446 M usaUSA
Certara Certara
CERT
$ 10.07 7.59 % $ 1.62 B usaUSA
Cullinan Management Cullinan Management
CGEM
$ 16.04 3.42 % $ 966 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.31 0.43 % $ 216 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.12 0.86 % $ 131 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 32.59 2.97 % $ 2.16 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 3.41 1.46 % $ 41.6 M israelIsrael
Cellectis S.A. Cellectis S.A.
CLLS
$ 1.41 0.48 % $ 141 M franceFrance
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 1.67 0.56 % $ 4.36 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 5.3 0.7 % $ 2.35 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.11 1.72 % $ 12.5 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 21.87 0.05 % $ 692 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 122.03 4.99 % $ 12.7 B usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 5.85 0.16 % $ 77.9 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.14 1.79 % $ 76.2 M usaUSA
Curis Curis
CRIS
$ 0.79 0.1 % $ 10.4 M usaUSA
CorMedix CorMedix
CRMD
$ 7.26 0.97 % $ 523 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 57.34 3.45 % $ 5.16 B schweizSchweiz
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 10.74 0.09 % $ 848 M usaUSA
Champions Oncology Champions Oncology
CSBR
$ 4.97 0.61 % $ 68.7 M usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
$ 2.58 0.78 % $ 356 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
$ 0.52 0.4 % $ 5.75 M usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 24.36 1.27 % $ 2.31 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 2.42 4.76 % $ 19.4 M usaUSA
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 62.7 0.2 % $ 7.53 M usaUSA
Daré Bioscience Daré Bioscience
DARE
$ 0.84 0.04 % $ 9.39 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 10.44 0.47 % $ 1.46 B franceFrance
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 8.42 2.31 % $ 396 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 19.91 0.41 % $ 3.44 B usaUSA